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1. Introduction 
 
Multiple Myeloma (MM) is a clonal plasma cell neoplasma sensitive to several antineoplastic 
agents including alkylating agents, anthracyclines, corticosteroids, radiation therapy, 
immunomodulators and proteasome inhibitors. It accounts for approximately 10% of all 
hematologic malignancies [1]. In recent years, major progress has been made in its treatment, 
thanks to the introduction of novel agents, such as bortezomib and lenalidomide used in 
combination with conventional drugs, including dexamethasone [2-7], and to the improvement of 
transplant procedures [8,9]. 
 
 
2. Autologous hematopoietic progenitor cell transplantation for 
multiple myeloma 
 
 
 
  
Over the last decade, autologous hematopoietic progenitor cell transplantation (AHPCT) has been 
considered the standard of care for younger patients with newly diagnosed MM [10,11], based on 
the increased rate of complete response (CR), prolonged disease free (DFS) and overall survival 
(OS), compared with conventional chemotherapy (CC) in several randomized studies [12,13]. 
However, not all the studies published have clearly demonstrated the superiority of AHPCT [14-16] 
and a systematic review and meta-analysis has shown a significant benefit with single AHPCT in 
terms of prolonged progression-free survival (PFS), but not of OS [17]. More recently, to further 
reduce residual disease, some studies evaluated the efficacy of additional therapies after AHPCT 
either based on a second autograft (‘tandem autologous transplant') or on a reduced-intensity/non-
myeloablative conditioning followed by allogeneic hemopoietic progenitor cell transplantation 
(allo-HPCT). The tandem AHPCT approach achieved improvement in OS [18,19] even though a 
survival benefit was mainly seen in patients who failed to achieve at least very good partial 
remission as defined by the European Group for Blood and Marrow Transplantation [20,21]. An 
alternative to autotransplantation up-front is to delay high-dose chemotherapy (HDC) with AHPCT 
at the time of relapse. Although in a study the length of OS for patients receiving early or late 
AHPCT after CC was equivalent, early AHPCT was associated with a longer event-free survival 
(EFS) and better quality of life [22]. 
In patients eligible to receive HDC, the role of AHPCT continues to evolve in the novel agent era 
[23-25] and the new drugs have been incorporated into the therapeutic algorithm along with 
AHPCT [26-28]. Autotransplantation, applied after novel-agent-based induction regimens, provides 
further improvement in the depth of response, a gain that translates into extended disease control 
[29] and, however, the International Myeloma Working Group (IMWG) recommends that AHPCT 
should be offered at some point in the course of the treatment program for a medically fit patient 
[29]. 
Based on these studies, high-dose melphalan (HDM) (dose range 140 – 220 mg/m2) followed by 
AHPCT has become an integral treatment modality [30-32] and MM remains the leading indication 
for AHPCT in Europe and in the United States [33,34]. High-dose melphalan rarely causes severe 
toxicity to major organs with the exception of the gastrointestinal tract where mucositis still 
represents a frequently observed extra-hematological toxicity [35]. 
Moreover, better supportive care, the extensive use of peripheral blood progenitor cells (PBPCs) 
and post-transplant growth factors have gradually made HDM less toxic and it should now be 
considered a safe procedure [25,31,33,36,37] with a transplant-related mortality (TRM) down to 1 – 
5% [38-43]. In Europe, virtually all autologous transplants are performed using G-CSF-mobilized 
PBPCs [33] and their use results in a rapid and durable full hematopoietic recovery [38-40]. 
Improvement in oral antibiotic prophylaxis [41-43] and the use of once-daily dosing i.v. parenteral 
antibiotics [44-47] have clearly simplified the management of infectious complications, major cause 
of morbidity in this setting. 
 
 
2. Outpatient care programs 
 
Patients who undergo AHPCT are commonly admitted to bone marrow transplant units on a wholly 
inpatient program. In this setting, central venous catheter (CVC) insertion, HDC administration, 
hemopoietic progenitor cell infusion and supportive care during neutropenia are carried out in 
positive-pressure reverse isolation rooms with a hospital stay of approximately 3 – 4 weeks [48]. 
The growing demand for AHPCT significantly increases waiting lists and generate concerns about 
the appropriate use of health care resources and patient's quality of life. Over the past years, a 
number of studies have investigated safety, efficacy and potential cost-advantages of reducing 
hospital stay for patients undergoing AHPCT [49-60]. Thus, outpatient transplant programs have 
been proposed for various hematological and non-hematological malignancies [61,62]. 
The most representative clinical trials of AHPCT as an outpatient procedure are summarized in 
Table 1. Studies usually conclude that HDC is feasible and safe in the outpatient setting given the 
availability of hematopoietic growth factors, myeloablative drugs that do not induce severe 
mucositis and efficacious antimicrobial prophylaxis, which lowers neutropenia-related complication 
rates [57]. The easy administration of HDM and the relatively low extra-medullary toxicity, 
including nausea and vomiting, and the short period of neutropenia [63-65] make MM patients ideal 
candidates for outpatient transplant programs. 
 
 Table 1. Autologous hemopoietic progenitor cell transplantation through an outpatient 
program. Results of clinical trials.  
 
 
 
 
3.1 Early-discharge model (EDM)  
 
In this model (Figure 1), CVC insertion, fluid infusion, HDC administration and HPC infusion are 
carried out in positive-pressure reverse isolation rooms, whereas supportive care of the aplastic 
phase is carried out on the outpatient service. During the past decade, several experiences have been 
published. Historically, one of the first studies was published by Peters et al. in a cohort of patients 
with primary metastatic breast cancer (MBC). The authors [59] reported a 28.5% reduction in days 
of hospitalization in 110 women who underwent HDC with cyclophosphamide, cisplatin and 
carmustine followed by HPC support. Approximately 70% of these patients required no re-
admission or only a brief hospital stay of 1 – 4 days. Overall, charges related to the transplant 
procedure were reduced by 50% over the following 2 – 5 years after the implementation of the 
outpatient transplant program. 
 
Figure 1. Hemopoietic Progenitor Cell Transplantation. Outpatients Early Discharge model. 
 
 
One EDM approach was reported by Ferrara et al. Preliminary findings on 28 MM patients showed 
feasibility and safety of the procedure without early TRM and a 36% rate of re-admission [51]. 
Another study from the same group reported on a series of MM patients who underwent an 
autograft on an outpatient program using either post-transplant single-dose PEG-Filgrastim or 
conventional daily G-CSF. The conditioning was HDM (140 – 200 mg/m2). Overall, the re-
admission rate was 32% (36 out of 161 procedures). There was no statistically significant difference 
in re-admissions between the two cohorts: 12% (6/48) in the PEG-Filgrastim group versus 26% 
(30/113) [66]. 
Montanari et al. [64] have recently reported on an outpatient transplant program in MM and 
lymphoma patients consisting of the inpatient administration of HDC and stem cell infusion 
followed by early discharge on day 1. High-dose chemotherapy regimens were HDM (200 mg/m
2
) 
for MM and carmustine, etoposide, cytarabine and melphalan (BEAM regimen) [67] for Hodgkin 
lymphoma and non-Hodgkin lymphoma (NHL) patients. Amifostine was administered before 
melphalan infusion. Re-admission rates were 11% for MM patients and 27% for lymphoma 
patients, respectively. Amifostine is a cytoprotector that detoxifies reactive metabolites of platinum 
and alkylating agents [68,69]. Its potential role in preventing extra-hematological toxicity after 
HDM has been investigated in a retrospective study that suggested that the drug could reduce severe 
mucositis and, consequently, the use of analgesic drugs [70,71]. 
In the same outpatient setting, Olivieri et al. [72] evaluated the post-transplant combined 
administration of erythropoietin with filgrastim. Not only was this combination associated with 
shorter duration of neutropenia, but also with significantly improved clinical outcomes after HDC. 
Importantly, this procedure translated into significant cost savings and, in the future, may be 
extended to elderly medically fit patients. Nevertheless, currently the use of erythorpietin or 
amifostine remains unclear whether in the inpatient or outpatient setting. 
Recently, Faucher et al. [73] reported the first randomized study comparing EDM with standard 
inpatient AHPCT on a cohort of 131 patients with non-leukemic malignant diseases. In both arms A 
and B, HDC and stem cell infusion occurred during the hospital stay. Early-discharge model in arm 
A allowed discharge on day 0, home stay with a caregiver and outpatient follow-up. Patients on arm 
B were followed up as inpatients. The study reported an 86% rate of re-admission which usually 
occurred during the first week (87% of re-admitted patients) and mainly before hematological 
recovery (for 93%). The EDM within the French health system, while safe and feasible, was highly 
dependent on economic–social factors. In fact, 39% of patients with an indication for HDC could 
not be discharged early because of social or psychological reasons (lack of a caregiver, living far 
away from the transplant center or patient will). In particular, lack of a caregiver was a major 
limitation to outpatient transplant programs [74]. 
 
3.2 Delayed admission model (DAM)  
 
In this model (Figure 2), HDC and HPC infusion are performed on the outpatient service, whereas 
the supportive care of the aplastic phase is given in positive-pressure reverse isolation rooms. 
 
Figure 2. Hemopoietic Progenitor Cell Transplantation. Outpatients Delayed Admission Model. 
 
 
 
Weaver et al. [75] reported on the outcome of 83 NHL patients who had failed first-line  
chemotherapy and received HDC with carmustine, etoposide, cytarabine and cyclophosphamide 
(BEAC regimen) [76] followed by AHPCT as outpatients. The outpatient treatment facility was 
designed ‘ad hoc' with daily follow up for complications such as febrile neutropenia or inadequate 
oral intake. Patients were hospitalized only during the aplastic phase and their median duration of 
hospital stay was two weeks. 
Another DAM approach was proposed by Anastasia et al. [49]. Discharge was scheduled on day 1 
and re-admission on day 5. One hundred forty-four patients with various hematological and non-
hematological malignancies entered the program. Early discharge was feasible in 86% (123/144 
procedures) and only a small proportion (5%) of discharged patients was re-admitted before day 5, 
mainly due to severe mucositis or fever. These findings, however, do not strongly support that the 
DAM model may significantly reduce the duration of hospitalization and its costs when compared 
to other models. 
3.3 Total outpatient model (TOM)  
This approach (Figure 3) is associated with the shortest duration of hospitalization [58,77,78]. High-
dose chemotherapy and HPC infusion are performed as outpatients. After HPC infusion, patients 
are followed daily on the outpatient service where they receive supportive care: growth factor 
injections, red blood cell and platelet transfusions, and prophylactic therapy with oral antibiotics, 
antiviral and antifungal medications. 
 
Figure 3. Hemopoietic Progenitor Cell Transplantation. Total Outpatient Model. 
 
 
Gerzt et al. [78] reported on the feasibility of the TOM model in 716 MM patients who underwent 
AHPCT at the Mayo Clinic in Rochester, MN (USA). The study showed that 278 (39%) out of the 
716 patients completed the entire procedure without requiring admission. The median duration of 
hospitalization for all patients was 4 days. This experience showed that outpatient transplant was 
feasible for all patients with MM and resulted in shorter hospital stays and low TRM rates in both 
high-risk and low-risk patients. However, it should be observed that most patients, who lived far 
from the Center, had to temporarily find lodging in local hotels to allow prompt access to the 
outpatient care unit. This policy may not negligibly increase the out-of-pocket cost burden to the 
patients. 
Using a TOM model, Kassar et al. [65] stressed the remarkable consistency in the time to 
neutropenia (from the HPC infusion day to the day with ANC < 0.5 × 10
9
/L) and its duration in 89 
MM patients treated with HDM (140 – 200 mg/m2). Nearly two-thirds of patients became 
neutropenic on day 5 and the remaining developed neutropenia one day earlier or later. Duration of 
neutropenia was ≤ 5 days in 80% of the patients and ≤ 7 days in all. 
3.4 Mixed inpatient–outpatient model (MIOM)  
This program has primarily been designed and employed in Italy [63]. Central venous catheter 
insertion, fluid infusion, HDM, as well as supportive care during the aplastic phase were carried out 
on the outpatient service (Figure 4). Multiple myeloma patients were admitted for only two days 
during which HPC were infused. The inpatient HPC infusion is mandatory to obtain the optimal 
reimbursement according to the Italian diagnosis-related group (DRG) system (Ministry Decree, 
April 15, 1994 and Gazzetta Ufficiale n. 107, May 10, 1994). A prerequisite for this program was 
the availability of dedicated specialized staff and an outpatient service operating 12 h/day including 
week-ends. The patients who did not live within easy reach from the Center (expected time from 
home to hospital by car or by public transportation not exceeding 45 min) were temporarily staying 
in nearby hotels free-of-charge and could easily reach emergency phone numbers at all times. 
Clinical outcomes of this program were compared with those of MM patients traditionally 
transplanted according to a wholly inpatient procedure. Patients on the MIOM program had a 
significant reduction of the hospital stay without increased toxicity. Overall, 6.7% were not 
discharged after the HPC infusion, and among those discharged as planned, 43% were re-admitted 
for a median hospital stay of 9 days, significantly shorter than the median of 20 days observed with 
conventional inpatient AHPCT. These data are consistent with Jagannath's report [55] where only 
21% of the outpatient population required re-admission after AHPCT. 
 
Figure 4. Hemopoietic Progenitor Cell Transplantation. Mixed Inpatient–Outpatient Model. 
 
 
3.5 At-home management of the aplastic phase following HDC and AHPCT for hematological and 
non-hematological malignancies  
Westermann et al. [79] developed a home care program for patients undergoing HDC with AHPCT 
for malignant lymphomas conditioned with BEAM, and breast cancer or germ-cell cancer treated 
with three courses of high-dose cyclophosphamide, thiotepa and carboplatin [80]. Patients were 
discharged on the day of HPC infusion if they resided in the surrounding areas. All supportive care, 
which included blood draws from CVC, transfusion of blood products, and infusion of parenteral 
antibiotics, was delivered at home by highly specialized nursing staff. No increased toxicity was 
observed and most patients appreciated the opportunity to stay with their families right after HPC 
reinfusion without increasing patient's anxiety. For most patients and their families major advantage 
was the opportunity to be together in a non-medical environment. No unexpected emergencies 
occurred and toxicity was similar to that of the traditional inpatient transplant program without any 
transplant-related death. A similar multi-center experience has recently been proposed in Italy for 
MM patients [81]. 
3.6 Outpatient programs in the setting of allografting  
Allo-HPCT after reduced-intensity conditionings (RIC) has been associated with decreased early 
toxicity [82]. This suggested that the procedure could be performed on an outpatient basis. In 
particular, trials which employed non-myeloablative TBI-based conditionings showed that the 
procedure could fully and safely be administered as outpatient [83-85]. One study showed a median 
reduction from 27 days to 9 days of hospital stay using an outpatient approach [84]. These findings 
form the basis for larger outpatient transplant programs after RIC conditionings. 
 
 
3. Outpatient management: reasons for hospitalization 
 
Gluck et al. [54] identified five reasons for hospitalization during an outpatient program: i) 
unexpected severe complications, related to the administration of the preparative regimens, such as 
nausea and vomiting leading to severe side effects (i.e., dehydration); ii) need of large volumes of iv 
fluids; iii) dimethylsulphoxide (DMSO)-related toxicity; iv) neutropenic fever; and v) severe extra-
hematological toxicities such as mucositis, diarrhea or significant hemorrhage. 
However, after introducing the technique of DMSO depletion, toxicities have consistently been 
reduced [63,86,87] and hydration fluids, electrolytes administration and antiemetic therapy can 
easily be administered on an outpatient basis. Post-transplant neutropenic fever can successfully be 
managed in the ambulatory setting [88] with several antibiotics that require once-daily i.v. 
administration [47-50], and only infections that result in hemodynamic instability require 
admission. Severe mucositis is an important complication that often predicts the onset of fever 
suggesting that the outpatient approach per se is not a major risk factor for fever [63]. Progressive 
mucositis that prevents appropriate oral intake or causes severe pain intractable with oral or 
transdermal narcotics requires admission [78]. Some authors reported the results of studies of 
cryotherapy for the prevention of HDM-induced oral mucositits in patients undergoing AHPCT 
[89,90]. They showed that oral cryotherapy contributes significantly to a decrease in the incidence 
and duration of grades 3 – 4 oral mucositis, as do the uses of narcotics and total parenteral nutrition. 
A Cochrane review of this area was most recently published [91]. There were 10 interventions, 
where there was more than one trial in the meta-analysis, that showed some statistically significant 
evidence of a benefit (albeit sometimes weak) for either preventing or reducing the severity of 
mucositis, compared to either a placebo or no treatment. These ten interventions were: aloe vera, 
amifostine, cryotherapy, granulocyte-colony stimulating factor (G-CSF), intravenous glutamine, 
honey, keratinocyte growth factor, laser, polymixin/tobramycin/amphotericin (PTA) antibiotic 
pastille/paste and sucralfate. Two interventions, cryotherapy (ice chips) and keratinocyte growth 
factor (palifermin®) showed some benefit in preventing mucositis. Sucralfate is effective in 
reducing the severity of mucositis, and a further seven interventions, aloe vera, amifostine, 
intravenous glutamine, G-CSF, honey, laser and antibiotic lozenges containing PTA showed weaker 
evidence of benefit. By contrast, transfusion of blood products can properly be planned on an 
outpatient basis. 
Overall, the success of the program also depends upon a proper patient selection. Younger myeloma 
patients and those with serum creatinine levels less than 1.5 mg/dL were more likely to complete 
transplant programs as outpatients [78]. It is controversial whether the disease status affects the 
efficacy of the program. Montanari [64] showed that disease status may be correlated with the risk 
of re-admission after early discharge. In another study, disease status at the time of transplant did 
not appear to affect length of hospitalization if patients underwent transplant within 12 months from 
diagnosis [78]. 
 
 
4. Outpatient transplant programs: cost analysis 
 
Outpatient programs have mainly been urged by the growing demand for autografting in 
hematological malignancies and by continuous cost-containment pressures. 
Barosi et al. [92] reported that the length of hospitalization accounted for most of the costs of an 
autograft at a single Italian institution. The authors applied a Markov model [93] to simulate the 
entire procedure by the probabilities of key events and costs. The number of days spent in hospital 
was the major cost factor accounting for 80% of the total cost of the procedure. 
One study reported a statistically significant correlation between the length of hospital stay and total 
costs, which were primarily associated with nursing care personnel's salaries [94]. In another study, 
the costs of a mean duration of hospitalization of 31 days (range, 27 – 37 days) during the autograft 
far exceeded reimbursement [95]. 
In the United States, the management of autografting for myeloma in the outpatient setting has 
allowed for remarkable financial savings, mainly due to a shorter length of hospitalization and 
lower drug and laboratory costs [55]. Cost savings associated with outpatient autografting have 
been estimated up to 25% [96]. Moreover, given that most outpatients did not receive parenteral 
nutrition or antibiotics, differences in costs between inpatient and outpatient treatments may 
probably have been underestimated. 
Rizzo et al. [60] confirmed that both outpatient-based allogeneic and autologous HPCT are feasible 
with regard to conditioning regimen delivery and management of clinical complications. 
Importantly, the study also shows that significant reductions in unadjusted total medical charges to 
payers may not result from simply shifting care to the outpatient setting for all transplant patients. 
Of note, the results suggested that a select group of patients, in particular, those with standard risk 
of disease recurrence, may derive substantial cost savings from an outpatient-based transplant 
program. 
In the Italian study by Anastasia et al. [49], the authors did not report a formal cost analysis. 
However the job-order system of their institution is 418 Euros daily for inpatient care, which 
includes a summary of all costs such as room, meals, nursing care. The introduction of their mixed 
inpatient–outpatient transplant program allowed cost savings up to 1672 Euros/patient without any 
negative impact on patient's outcome. 
In a French randomized study [73], shifting from inpatient care to early discharge programs allowed 
cost savings up to 19% in a group of patients who were actually discharged early. However, 
considering all randomized patients, the program showed a mean cost per patient only 6% inferior 
as compared with that of the traditional inpatient group. 
Overall, though it is difficult to compare cost analyses among different countries, all studies 
conclude that outpatient programs lead to cost savings from 7 up to 47% [50,55,58,73]. 
 
 
5. Outpatient transplant programs: quality of life 
 
The most of outpatient studies did not perform a formal study dealing with quality of life. However, 
this aspect should be explored, because the feeling is that outpatient patients might have a better 
perception of well-being than do those transplanted in the inpatient context. This sensation is in line 
with a report dealing with a comparison between the psychosocial impact of inpatient–outpatient 
autologous transplants [97]. In this study, Summers et al. found that outpatients had significantly 
higher scores for emotional well-being and global quality of life than did inpatients. 
 
 
6. Expert opinion 
 
The role of HDM followed by AHPCT in the treatment of MM continues to evolve in the novel 
agent era and the IMWG recommends that AHPCT should be offered at some point in the course of 
the treatment program for a medically fit patient. Various models have shown that the AHPCT 
programs may be performed in the outpatient setting and may highly contribute to shorten waiting 
lists and to considerably cut health costs [98]. The easy administration of HDM and the relatively 
short neutropenia and the limited extra-marrow toxicity make MM patients ideal candidates for 
outpatient transplant programs. The recommendations for the different models are summarized in 
Table 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Potential indications for the different outpatient models. 
 
 
The key findings and weaknesses in the research done in this field so far are: 
 a positive-pressure reverse isolation room during the neutropenic period is not mandatory in 
MM patients. This finding should offset the reconstruction of the global outpatient care 
model, requiring extensive coordination and implementation of resources; 
 reduced length of hospitalization results in remarkable cost containments [55,92] and 
reduced exposure to hospital micro-organisms may have a favorable effect on complication 
rates [63,99]; 
 neutropenic fever can be managed with single daily dose broad-spectrum antibiotics as first-
line treatment in the majority of cases and only few cases require combination antibiotic 
therapy [44,100]; 
 mucositis appears the most serious side-effect in the setting of outpatient transplant 
programs. The administration of cytoprotectors may reduce its severity and ameliorate 
symptoms [64,89-91,101]; 
 successful outpatient care requires the availability of a permanent outpatient service where 
medications and supportive care can rapidly and efficiently be provided by highly trained 
personnel [50,63]; 
 patient concerns and anxiety about quality of care, the lack of a caregiver and financial 
constraints may represent important limitations to the large application of outpatient 
transplant programs. However, there is evidence that patients prefer being treated as 
outpatients and that their quality of life is thereby improved [97]; 
 outpatient transplant programs cannot be offered to all patients. Ideal candidates may be 
those who are asymptomatic and fully active, who have a full-time caregiver and who can 
reside within easy reach from the transplant center. 
In the future, it is crucial to establish largely accepted guidelines for early discharge after stem cell 
infusion and re-admission. Major medical conditions that could require prompt hospitalization 
include declining performance status not compatible with outpatient care, progressive mucositis that 
precludes oral intake, intractable pain from mucositis that cannot be controlled with oral or 
transdermal narcotics and infections that lead to hemodynamic instability. Moreover, the number of 
studies that compare inpatient and outpatient transplant programs are limited and essentially 
compare retrospective or prospective patient cohorts with historical groups or case control groups. 
Future trials should focus on the analysis of large prospective multi-center outpatient programs, 
which may identify patient subgroups who may most benefit from this innovative approach. 
Article highlights. 
 The role of high-dose melphalan (HDM) followed by autologous hemopoietic progenitor 
cell transplantation (AHPCT) in the treatment of multiple myeloma continues to evolve in 
the novel agent era. 
 The International Myeloma Working Group recommends that AHPCT should be offered at 
some point in the course of the treatment program for a patient eligible to receive HDM. 
 There are considerable concerns regarding the appropriate use of health care resources to 
reduce costs and waiting lists associated with AHPCT. 
 One of the strategies to reach this goal is outpatient-based (OpB) AHPCT. 
 Various models have shown that the procedure is feasible and safe and associated with an 
improvement of quality of life. 
 Ideal candidates may be those who are asymptomatic and fully active, who have a full-time 
caregiver and who can reside within easy reach from the transplant center. 
This box summarizes key points contained in the article. 
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